← Back to Search


INV-202 for Metabolic Syndrome

Phase 1
Waitlist Available
Research Sponsored by Inversago Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights


This trial is testing a new drug, INV-202, to see if it is safe and effective in people with metabolic syndrome.

Eligible Conditions
  • Metabolic Syndrome


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number and Frequency of Adverse Events
Secondary outcome measures
Pharmacokinetic profile of INV-202

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: INV-202Experimental Treatment1 Intervention
INV-202 25mg by mouth once daily
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by mouth once daily
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Find a Location

Who is running the clinical trial?

Inversago Pharma Inc.Lead Sponsor
3 Previous Clinical Trials
523 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
243 Patients Enrolled for Metabolic Syndrome
Glenn D Crater, MDStudy DirectorInversago Pharma
1 Previous Clinical Trials
40 Total Patients Enrolled
~11 spots leftby Jul 2025